Skip to main content

TPCA-1 (C09-1073-924)

Aladdin

Catalog No.
C09-1073-924
Manufacturer No.
T408266-1ml
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $285.30
List Price: $317.00

InformationTPCA-1 (GW683965) is an inhibitor ofIKK-2withIC50of 17.9 nM in a cell-free assay, inhibitsNF-κBpathway, exhibits 22-fold selectivity over IKK-1. TPCA-1 is also an inhibitor ofSTAT3and enhancesapoptosis.In vitroIn a time-resolved

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
InformationTPCA-1 (GW683965) is an inhibitor ofIKK-2withIC50of 17.9 nM in a cell-free assay, inhibitsNF-κBpathway, exhibits 22-fold selectivity over IKK-1. TPCA-1 is also an inhibitor ofSTAT3and enhancesapoptosis.In vitroIn a time-resolved fluorescence resonance energy transfer assay, TPCA-1 inhibits human IKK-2 activity with an IC50 of 17.9 nM. In addition, TPCA-1 is demonstrated to be ATP-competitive. Besides, TPCA-1 exhibits IC50 values of 400 nM and 3600 nM against IKK-1 and JNK3, respectively. TPCA-1 inhibits the production of TNF-α, IL-6, and IL-8 in a concentration-dependent manner, exhibiting IC50 values of 170, 290, and 320 nM, respectively. TPCA-1 inhibits glioma cell proliferation, as well as TNF-induced RelA (p65) nuclear translocation and NFκB-dependent IL8 gene expression. Importantly, TPCA-1 inhibits IFN-induced gene expression, completely suppressing MX1 and GBP1 gene expression, while having only a minor effect on ISG15 expression.In vivoProphylactic administration of TPCA-1 at 3, 10, or 20 mg/kg, i.p., b.i.d., results in a dose-dependent reduction in the severity of murine collagen-induced arthritis (CIA). The significantly reduced disease severity and delay of disease onset resulting from administration of TPCA-1 at 10 mg/kg, i.p., b.i.d. are comparable to the effects of the antirheumatic drug, etanercept, when administered prophylactically at 4 mg/kg, i.p., every other day. Nuclear localization of p65, as well as levels of IL-1beta, IL-6, TNF-alpha, and interferon-gamma, is significantly reduced in the paw tissue of TPCA-1- and etanercept-treated mice. In addition, administration of TPCA-1 in vivo results in significantly decreased collagen-induced T cell proliferation ex vivo. Therapeutic administration of TPCA-1 at 20 mg/kg, but not at 3 or 10 mg/kg, i.p., b.i.d., significantly reduces the severity of CIA, as does etanercept administration at 12.5 mg/kg, i.p., every other day.Cell Datacell lines:Concentrations:0-50 μMIncubation Time:3 daysPowder Purity:≥98%. Specification: 10mM in DMSO Molecular Formula: C12H10FN3O2S Molecular Weight: 279.29
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
0.85 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
T408266-1ml
CAS:
507475-17-4
Product Size:
1ml


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.